首页 中华结核和呼吸杂志 2015年38卷6期 抗菌药物超说明书用法专家共识
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 诊疗方案 •
抗菌药物超说明书用法专家共识
中国医药教育协会感染疾病专业委员会
中华结核和呼吸杂志编辑委员会
中国药学会药物临床评价研究专业委员会
作者及单位信息
·
DOI: 10.3760/cma.j.issn.1001-0939.2015.06.005
0
0
0
0
0
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
药品说明书是临床医师处方的最重要依据,但因药物在临床应用中不断有新的发现与经验积累,再加上药物临床注册试验周期长、药品说明书更新相对滞后,因此,超说明书用药有其科学性与合理性,在临床中往往是不可避免的,甚至有时也会成为挽救生命的唯一手段。与其他类药物相比,抗菌药物用于敏感细菌的超适应证用法或用于不够敏感细菌的超剂量用法更普遍、更常见。文献报道,在25个研究共7亿2千余万处方中,成人重症患者抗菌药物超说明书用法处方占19%~43%,普通门诊也占23%@ [ 1 ] 。可见抗菌药物的超说明书用法是一种在临床业已存在的较普遍的现象。
引用本文
中国医药教育协会感染疾病专业委员会,中华结核和呼吸杂志编辑委员会,中国药学会药物临床评价研究专业委员会. 抗菌药物超说明书用法专家共识[J]. 中华结核和呼吸杂志,2015,38(6):410-444.
DOI:10.3760/cma.j.issn.1001-0939.2015.06.005PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
5分
[累计个]
向我们报错
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
前言
药品说明书是临床医师处方的最重要依据,但因药物在临床应用中不断有新的发现与经验积累,再加上药物临床注册试验周期长、药品说明书更新相对滞后,因此,超说明书用药有其科学性与合理性,在临床中往往是不可避免的,甚至有时也会成为挽救生命的唯一手段。与其他类药物相比,抗菌药物用于敏感细菌的超适应证用法或用于不够敏感细菌的超剂量用法更普遍、更常见。文献报道,在25个研究共7亿2千余万处方中,成人重症患者抗菌药物超说明书用法处方占19%~43%,普通门诊也占23%@
[
1
]。可见抗菌药物的超说明书用法是一种在临床业已存在的较普遍的现象。
超说明书用法也称未注册用法(off-label uses,unlabeled uses,out of label usage or outside of labeling),其内容包括超适应证、超剂量、超疗程、超适应人群及改变说明书中规定的用药途径与用药间隔时间等。
2013版"赫尔辛基宣言"
[
2
]在最后一节中强调指出:"医生在治疗患者时,如无已证实的有效方法或其他已知方法均无效时,当医生判断有挽救生命、恢复健康、减轻痛苦的可能,在征得患者或监护人同意后,参考专家建议可采用未经证实的方法"。而本共识推荐的用法均是经过临床实践证明较为安全有效的用法。目前,我国有关超说明书用药的法规尚不完善,医师选择超说明书用药将承担更大的风险。本共识的主要宗旨是给读者提供有参考价值的、常用且重要的抗菌药物超说明书应用的科学信息,并不涉及超说明书用法的批准程序,也不涉及婴幼儿、孕妇及哺乳期妇女等特殊人群。
临床医师应自始至终时刻权衡治疗对象的获益和风险,在遵守国家、地方政府和所在医院有关法律规定的基础上,参照本专家共识提供的信息,针对不同的治疗对象制定具体治疗方案,同时本共识也强调,当遵照说明书就能达到安全有效的治疗目的时,应尽量避免选择超说明书用法。
本共识推荐的证据等级划分参照以下原则:A级:国外说明书已载入或国内外权威指南作为A级推荐;B级:本共识制定者认可的指南中作为B级推荐或有循证医学证据支持、发表在权威学术期刊上的研究结果;C级:学术刊物发表的有一定科学根据的研究结果。本共识不收录以个案报告及专家个人意见为依据的用法。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Tansarli GS , Rafailidis PI , Kapaskelis A ,et al. Frequency of the off-label use of antibiotics in clinical practice: a systematic review[J]. Expert Rev Anti Infect Ther, 2012,10(12):1383-1392.
[2]
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects[J]. JAMA, 2013,310(20):2191-2194.
[1]
青霉素G中文说明书. 2010年版. 华北制药集团有限责任公司.
[2]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(9):1267-1284.
[3]
Baddour LM , Wilson WR , Bayer AS . Infective endocarditis diagnosis, antimicrobial therapy, and management of complications[J]. Circulation, 2005,111(23):e394-e434.
[1]
氨苄西林中文说明书. 2010年版. 联邦制药国际控股有限公司.
[2]
Wilson W , Taubert KA , Gewitz M ,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group[J]. Circulation, 2007,116(15):1736-1754.
[3]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(9):1267-1284.
[1]
注射用头孢唑啉钠中文说明书. 2014年版. 华北制药集团有限责任公司.
[2]
CEFAZOLIN AND DEXTROSE
®(cefazolin sodium) for injection, package insert
. 2014. B BRAUN US Inc.
[3]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Surg Infect (Larchmt), 2013,14(1):73-156.
[4]
中华医学会外科学分会,中华外科杂志编辑委员会. 围手术期预防应用抗菌药物指南[J]. 中华外科杂志, 2006,44(23):1594-1596.
[5]
Sun J , Ding M , Liu J ,et al. Prophylactic administration of cefazolin prior to skin incision versus antibiotics at cord clamping in preventing postcesarean infectious morbidity: a systematic review and meta-analysis of randomized controlled trials[J]. Gynecol Obstet Invest, 2013,75(3):175-178.
[6]
Tanos V , Rojansky N . Prophylactic antibiotics in abdominal hysterectomy[J]. J Am Coll Surg, 1994,179(5):593-600.
[1]
注射用头孢噻肟钠说明书. 2012年版. 齐鲁制药有限公司.
[2]
CLAFORAN
®(cefotaxime sodium injection), Package Insert and Label Information
. 2014. Sanofi-Aventis U.S. LLC.
[3]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Surg Infect (Larchmt), 2013,14(1):73-156.
[4]
中华医学会外科学分会,中华外科杂志编辑委员会. 围手术期预防应用抗菌药物指南[J]. 中华外科杂志, 2006,44(23):1594-1596.
[5]
Woodfield JC , Van Rij AM , Pettigrew RA ,et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery[J]. Am J Surg, 2003,185(1):45-49.
[1]
头孢西丁中文说明书. 2014年版. 扬子江药业集团有限公司.
[2]
CEFOXITIN AND DEXTROSE
®(cefoxitin sodium), for injection. package insert. 2011
. B BRAUN US Inc.
[3]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Surg Infect (Larchmt), 2013,14(1):73-156.
[4]
Griffith DE , Aksamit T , Brown-Elliott BA ,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontubereulous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007,175(7):367-416.
[5]
Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society[J]. Thorax, 2000,55(3):210-218.
[6]
中华医学会结核病学分会. 非结核分枝杆菌诊断与处理指南[J]. 中华结核和呼吸杂志, 2000,23(11):650-653.
[7]
中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2012,35(8):572-580.
[1]
头孢美唑中文说明书. 2010年版. 哈尔滨制药集团制药总厂.
[2]
ASHP Commission on Therapeutics. ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery[J]. Am J Health Syst Pharm, 1999,56(18):1839-1888.
[3]
中华医学会外科学分会,中华外科杂志编辑委员会. 围手术期预防应用抗菌药物指南[J]. 中华外科杂志, 2006,44(23):1594-1596.
[1]
注射用亚胺培南西司他丁钠说明书. 2012年版. 默沙东制药有限公司.
[2]
Jaruratanasirikul S , Sudsai T . Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion[J]. J Antimicrob Chemother, 2009,63(3):560-563.
[3]
Lee LS , Kinzig-Schippers M , Nafziger AN ,et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation[J]. Diagn Microbiol Infect Dis, 2010,68(3):221-225.
[4]
陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012,92(2):76-85.
[5]
中华医学会呼吸病学分会感染学组. 铜绿假单胞菌下呼吸道感染诊治专家共识[J]. 中华结核和呼吸杂志, 2014,37(1):9-15.
[1]
注射用美罗培南说明书. 2006年版. 浙江海正药业股份有限公司.
[2]
陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012,92(2):76-85.
[3]
Jaruratanasirikul S , Limapichat T , Jullangkoon M ,et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia[J]. Int J Antimicrob Agents, 2011,38(3):231-236.
[4]
Gilbert DN , Moellering RC , Eliopoulos GM . The Sanford guide to antimicrobial therapy[M]. 43rd. Antimicrobial Therapy, 2013:110-111.
[5]
中华医学会呼吸病学分会感染学组. 铜绿假单胞菌下呼吸道感染诊治专家共识[J]. 中华结核和呼吸杂志, 2014,37(1):9-15.
[6]
Falagas ME , Tansarli GS , Ikawa K ,et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis[J]. Clin Infect Dis, 2013,56(2):272-282.
[1]
比阿培南中文说明书. 2010年版. 江苏正大天晴药业股份有限公司.
[2]
Nakagawa Y , Suzuki K , Hirose T ,et al. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study[J]. J Infect Chemother, 2011,17(1):58-67.
[3]
比阿培南协作组. 比阿培南治疗血液系统疾病感染1 090例疗效的多中心回顾性研究[J]. 中华血液学杂志, 2013,34(9):807-809.
[1]
氨曲南说明书. 2013年版. 上海新先锋药业有限公司.
[2]
Quon BS , Goss CH , Ramsey BW . Inhaled antibiotics for lower airway infections[J]. Ann Am Thorac Soc, 2014,11(3):425-434.
[3]
Retsch-Bogart GZ , Burns JL , Otto KL ,et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection[J]. Pediatr Pulmonol, 2008,43(1):47-58.
[1]
注射用舒巴坦钠说明书. 2013年版. 华北制药集团有限责任公司.
[2]
陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012,92(2):76-85.
[3]
Munoz-Price LS , Weinstein RA . Acinetobacter infection[J]. N Engl J Med, 2008,358(12):1271-1281.
[4]
Betrosian AP , Xanthaki A , Douzinas EE . Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia[J]. J Infect, 2008,56(6):426-432.
[1]
注射用头孢哌酮钠/舒巴坦钠说明书. 2012年版. 辉瑞投资有限公司.
[2]
中华医学会血液学分会,中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南[J]. 中华血液学杂志, 2012,33(8):693-696.
[3]
Winston DJ , Bartoni K , Bruckner DA ,et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients[J]. Clin Infect Dis, 1998,26(3):576-583.
[4]
Bodey G , Abi-Said D , Rolston k ,et al. Imipenem or Cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients[J]. Eur J Microbiol Infect Dis, 1996,15(8):625-634.
[5]
卢锡京,黄晓军,沈志祥,等. 头孢哌酮/舒巴坦联合阿米卡星与亚胺培南/西司他丁经验性治疗中性粒细胞缺乏发热患者的对照研究[J]. 中华医院感染学杂志, 2007,17(7):874-877.
[1]
注射用哌拉西林/他唑巴坦说明书. 2014年版,齐鲁制药有限公司.
[2]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Am J Health-Syst Pharm, 2013,70(3):195-283.
[3]
Craig WA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men[J]. Clin Infect Dis, 1998,26(1):1-10.
[4]
Lodise TP Jr, Lomaestro B , Drusano GL . Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy[J]. Clin Infect Dis, 2007,44(3):357-363.
[5]
吕扬,闫昭,王东浩,等. 哌拉西林/他唑巴坦延长输注时间的优化给药方案与传统给药方式用于治疗医院获得性肺炎的研究[J]. 中华危重病急救医学, 2013,25(8):479-483.
[1]
国家药典委员会. 中华人民共和国临床用药须知:化学药和生物制品卷(2010年版)[M]. 北京:中国医药科技出版社, 2011:700.
[2]
注射用硫酸链霉素说明书. 2010年版. 山东鲁抗医药股份有限公司.
[3]
Kaplan JE , Benson C , Holmes KK ,et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009,58(RR-4):1-207.
[4]
Griffith DE , Aksamit T , Brown-Elliott BA ,et al. An Official ATS/IDSA Statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007,175(4):367-416.
[5]
桑福德. 抗微生物治疗指南[M]. 新译第43版. 北京:中国协和医科大学出版社, 2014:21.
[1]
注射用硫酸庆大霉素说明书. 2010年版. 山东鲁抗辰欣药业有限公司.
[2]
Kaplan JE , Benson C , Holmes KK ,et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009,58(RR-4):1-207.
[3]
Baddour LM , Wilson WR , Bayer AS ,et al. Infective Endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, american heart association: endorsed by the Infectious Diseases Society of America[J]. Circulation, 2005,111(23):e394-434.
[4]
Allison MC , Sandoe JA , Tighe R ,et al. Antibiotic prophylaxis in gastrointestinal endoscopy[J]. Gut, 2009,58(6):869-880.
[5]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery[J]. Surg Infect (Larchmt), 2013,14(1):73-156.
[6]
Oren L , Sprecher H , Finkelstein R ,et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial[J]. Am J Infect Control, 2013,41(12):1167-1172.
[7]
Saidel-Odes L , Polachek H , Peled N ,et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage[J]. Infect Control Hosp Epidemiol, 2012,33(1):14-19.
[1]
硫酸阿米卡星注射液说明书. 2010年版. 齐鲁制药有限公司.
[2]
Kaplan JE , Benson C , Holmes KK ,et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009,58(RR-4):1-207.
[3]
桑福德. 抗微生物治疗指南[M]. 新译第43版. 北京:中国协和医科大学出版社, 2014:135.
[4]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(9):1267-1284.
[5]
Kehinde EO , Al-Maghrebi M , Sheikh M ,et al. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate[J]. J Urol, 2013,189(3):911-915.
[1]
硫酸奈替米星注射液说明书. 2008年版. 浙江震元制药有限公司.
[2]
Mauracher EH , Lau WY , Kartowisastro H ,et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries[J]. Clin Ther, 1989,11(5):604-613.
[1]
硫酸妥布霉素注射液. 2010年版. 上海第一生化药业有限公司.
[2]
Tobramycin for Injection USP, 1.2 g, X-GEN Pharms. 2012-1-17.
[3]
Bratzler DW , Dellinger EP , Olsen KM ,et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Am J Health Syst Pharm, 2013,70(3):195-283.
[4]
Rehm SJ . Guidelines for antimicrobial usage 2012-2013[M]. New York:Professional Communications, Inc, 2012:73.
[5]
Riethmueller J , Ballmann M , Schroeter TW ,et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients[J]. Infection, 2009,37(5):424-431.
[1]
环丙沙星氯化钠注射液说明书. 2014年版. 拜耳医药保健有限公司.
[2]
CIPRO
®(ciprofloxacin for intravenous infusion)
. 2013. Bayer HealthCare Pharmaceuticals Inc. France.
[3]
Sadé J , Lang R , Goshen S ,et al. Ciprofloxacin treatment of malignant external otitis[J]. Am J Med, 1989,87(5A):138-141.
[4]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(9):1267-1284.
[1]
氧氟沙星片剂说明书. 2010年版. 北京双鹤药业股份有限公司.
[2]
Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2011.
[1]
左氧氟沙星片剂说明书. 2013年版. 第一三共制药北京有限公司.
[2]
左氧氟沙星氯化钠注射液说明书. 2013年版. 第一三共制药北京有限公司.
[3]
Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2011.
[4]
Malfertheiner P , Megraud F , O'Morain C ,et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht-Ⅲ Consensus Report[J]. Gut, 2007,56(6):772-781.
[5]
Malfertheiner P , Megraud F , O'Morain C ,et al. Management of helicobacter pylori infection- the maastricht-Ⅳ/florence consensus report[J]. Gut, 2012,61(5):646-664.
[6]
Nista EC , Candelli M , Zocco MA ,et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication[J]. Am J Gastroenterol, 2006,101(9):1985-1990.
[7]
Woodhead M , Blasi F , Ewig S ,et al. Guidelines for the management of adult lower respiratory tract infections-Full version[J]. Clin Microbiol Infect, 2011,17(Suppl 6):E1-E59.
[1]
莫西沙星片剂说明书. 2013年版. 拜耳医药保健有限公司.
[2]
盐酸莫西沙星氯化钠注射液说明书. 2013年版. 拜耳医药保健有限公司.
[3]
AVELOX
®(moxifloxacin for infusion)
. 2012. Bayer HealthCare Pharmaceuticals Inc. France.
[4]
AVELOX
®(moxifloxacin hydrochloride Injection)
. 2013. Bayer HealthCare Pharmaceuticals Inc. U S A.
[5]
那彦群,叶章群,孙颖浩,等. 中国泌尿外科疾病诊断治疗指南2014版[M]. 北京:人民卫生出版社, 2014:435-451.
[6]
Zhang G , Zou J , Liu F ,et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials[J]. Braz J Med Biol Res, 2013,46(7):607-613.
[7]
Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2011.
[8]
Ruslami R , Ganiem AR , Dian S ,et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomized controlled phase 2 trial[J]. Lancet Infect Dis, 2013,13(1):27-35.
[1]
红霉素说明书. 2005年版. 北京赛而生物药业有限公司.
[2]
注射用乳糖酸红霉素说明书. 2012年版. 湖南科伦制药有限公司.
[3]
李英姬,胡红,工藤翔二. 弥漫性泛细支气管炎和大环内酯类药物疗法[J]. 中华结核和呼吸杂志, 2002,25(7):421-423.
[4]
Schultz MJ . Macrolide activities beyond their antimicrobial effects:macrolides in diffuse panbronchiolitis and cystic fibrosis[J]. J Antimicrob Chemother, 2004,54(1):21-28.
[5]
Kudoh S , Azuma A , Yamamoto M ,et al. Improvement of survival in patients with diffuse panbronchiolitis[J]. Am J Respir Crit Care Med, 1998,157(6Pt 1):1829-1832.
[6]
Serisier DJ , Martin ML , McGuckin MA ,et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial[J]. JAMA, 2013,309(12):1260-1267.
[7]
Suzuki T , Yanai M , Yamaya M ,et al. Erythromycin and common cold in COPD[J]. Chest, 2001,120(3):730-733.
[1]
阿奇霉素片剂说明书. 2010年版. 辉瑞投资有限公司.
[2]
注射用阿奇霉素说明书. 2009年版. 辉瑞投资有限公司.
[3]
Phimda K , Hoontrakul S , Suttinont C ,et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus[J]. Antimicrob Agents Chemother, 2007,51(9):3259-3263.
[4]
Smyth AR , Bell SC , Bojcin S ,et al. European cystic fibrosis society standards of care: best practice guidelines[J]. J Cyst Fibros, 2014,13(S1):S23-S42.
[5]
Florescu DF , Murphy PJ , Kalil AC . Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis[J]. Pulm Pharmacol Ther, 2009,22(6):467-472.
[6]
Zhuo GY , He Q , Xiang-Lian L ,et al. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials[J]. Pulm Pharmacol Ther, 2014,29(1):80-88.
[7]
Albert RK , Connett J , Bailey WC ,et al. Azithromycin for prevention of exacerbations of COPD[J]. N Engl J Med, 2011,365(8):689-698.
[8]
Vos R , Vanaudenaerde BM , Ottevaere A ,et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?[J]. J Heart Lung Transplant, 2010,29(12):1358-1368.
[9]
Vos R , Vanaudenaerde BM , Verleden SE ,et al. A randomized controlled trial of azithromycin to prevent chronic rejection after lung transplantation[J]. Eur Respir J, 2011,37(1):164-172.
[10]
李惠萍,张苑,周瑛. 以阿奇霉素为主的综合措施治疗弥漫性泛细支气管炎的疗效(附51例报道)[J]. 上海医学, 2009,32(10):854-859.
[1]
克拉霉素说明书. 2011年版. 上海雅培制药有限公司.
[2]
Hashiba M , Baba S . Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis[J]. Acta Otolaryngol Suppl, 1996,525:73-78.
[3]
欧相林,黄江,曾祥毅. 长期小剂量克拉霉素对稳定期慢性阻塞性肺疾病的疗效观察[J]. 实用医学杂志, 2006,22(13):1558-1559.
[4]
李英姬,胡红,工藤翔二. 弥漫性泛细支气管炎和大环内酯类药物疗法[J]. 中华结核和呼吸杂志, 2002,25(7):421-423.
[1]
罗红霉素片剂说明书. 2010年版. 河南羚锐制药股份有限公司.
[2]
刘积锋,钟小宁,何志义,等. 小剂量罗红霉素对支气管扩张症稳定期治疗的影响[J]. 中华结核和呼吸杂志, 2012,35(11):824-827.
[3]
徐锋,徐作军,梁希军. 小剂量罗红霉素增加稳定期慢性阻塞性肺疾病常规治疗疗效的研究[J]. 国外医学呼吸系统分册, 2005,25(11):804-807.
[4]
Fokkens WJ , Lund VJ , Mullol J ,et al. European position paper on rhinosinusitis and nasal polyps 2012[J]. Rhinol Suppl, 2012, (23):3 p preceding table of contents,1-298
[5]
Wallwork B , Coman W , Mackay-Sim A ,et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis[J]. Laryngoscope, 2006,116(2):189-193.
[6]
Ogrendik M . Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized,double-blind, placebo-controlled trial[J]. Clin Ther, 2009,31(8):1754-1764.
[1]
多黏菌素B说明书. 2003年版. 上海新先锋药业有限公司.
[2]
Hodson ME , Gallagher CG , Govan JR . A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis[J]. Eur Respir J, 2002,20(3):658-664.
[3]
Westerman EM , De Boer AH , Le BP ,et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study[J]. J Cyst Fibros, 2007,6(4):284-292.
[4]
Berlana D , Llop JM , Manresa F ,et al. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis[J]. Pharmacotherapy, 2011,31(2):146-157.
[5]
Haworth CS , Foweraker JE , Wilkinson P ,et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection[J]. Am J Respir Crit Care Med, 2014,189(8):975-982.
[6]
Kofteridis DP , Alexopoulou C , Valachis A ,et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study[J]. Clin Infect Dis, 2010,51(11):1238-1244.
[7]
Tumbarello M , De Pascale G , Trecarichi EM ,et al. Effect of aerosolized colistin as adjunctive treatment on ty documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria[J]. Chest, 2013,144(6):1768-1775.
[8]
Korbila IP , Michalopoulos A , Rafailidis PI ,et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study[J]. Clin Microbiol Infect, 2010,16(8):1230-1236.
[9]
Florescu DF , Qiu F , McCartan MA ,et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression[J]. Clin Infect Dis, 2012,54(5):670-680.
[10]
Lu Q , Luo R , Bodin L ,et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii[J]. Anesthesiology, 2012,117(6):1335-1347.
[11]
Falagas ME , Rafailidis PI , Ioannidou E ,et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients[J]. Int J Antimicrob Agents, 2010,35(2):194-199.
[12]
Dalfino L , Puntillo F , Mosca A ,et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study[J]. Clin Infect Dis, 2012,54(12):1720-1726.
[13]
Vicari G , Bauer SR , Neuner EA ,et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia[J]. Clin Infect Dis, 2013,56(3):398-404.
[14]
Deryke CA , Crawford AJ , Uddin N ,et al. Colistin dosing and nephrotoxicity in a large community teaching hospital[J]. Antimicrob Agents Chemother, 2010,54(10):4503-4505.
[1]
万古霉素说明书. 2014年版. 美国礼来制药有限公司.
[2]
Tacconelli E , Cataldo MA , Albanese A ,et al. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant staphylococcus aureus[J]. J Hosp Infect, 2008,69(4):337-344.
[3]
Rybak MJ , Lomaestro BM , Rotschafer JC ,et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of america, the american society of health-system pharmacists, and the society of infectious diseases pharmacists[J]. Clin Infect Dis, 2009,49(3):325-327.
[4]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(9):1267-1284.
[5]
Theologis AA , Demirkiran G , Callahan M ,et al. Local intra-wound vancomycin powder decreases the risk of surgical site infections in complex adult deformity reconstruction: a cost analysis[J]. Spine, 2014,39(22):1875-1880.
[1]
替考拉宁说明书. 2013年版. 赛诺菲安万特制药有限公司.
[2]
得时高冻晶注射剂200 mg说明书. 2001年版. 赛诺菲安万特股份有限公司.
[3]
European Medicines Agency. Assessment report pursuant to Article 30 of Directive 2001/83/EC. Targocid and associated names. 2013, September 12. EMEA/CHMP/269452/2008
[4]
Nelson RL , Kelsey P , Leeman H ,et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults[J]. Cochrane Database Syst Rev, 2011(9):CD004610. doi:
10.1002/14651858.CD004610.pub4
.
[5]
Teicoplanin Sandoz
® teicoplanin 400 mg powder for injection 2013. MIMS/myDr
.
[6]
Ueda T , Takesue Y , Nakajima K ,et al. High-dose regimen to achieve novel target trough concentration in teicoplanin[J]. J Infect Chemother, 2014,20(1):43-47.
[7]
Matthews PC , Chue AL , Wyllie D ,et al. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity[J]. J Infect, 2014,68(1):43-49.
[8]
Ahn BJ , Yim DS , Lee DG ,et al. Teicoplanin dosing strategy for treatment of staphylococcus aureus in korean patients with neutropenic fever[J]. Yonsei Med J, 2011,52(4):616-623.
[1]
达托霉素说明书. 2010年版. 阿斯利康制药有限公司.
[2]
Seaton RA , Malizos KN , Viale P ,et al. Daptomycin use in patients with osteomyelitis: a preliminary report from the eu-core(sm) database[J]. J Antimicrob Chemother, 2013,68(7):1642-1649.
[3]
Lora-Tamayo J , Parra-Ruiz J , Rodriguez-Pardo D ,et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study[J]. Diagn Microbiol Infect Dis, 2014,80(1):66-71
[4]
Joseph WS , Quast T , Cogo A ,et al. Daptomycin for methicillin-resistant staphylococcus aureus diabetic foot infections[J]. J Am Podiat Med Assn, 2014,104(2):159-168.
[5]
Ramaswamy DP , Amodio-Groton M , Scholand SJ . Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series[J]. BMC Urology, 2013,13(1):33.
[6]
Liu C , Bayer A , Cosgrove SE ,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-55.
[7]
Kullar R , Davis SL , Levine DP ,et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study[J]. Pharmacotherapy, 2011,31(6):527-536.
[1]
注射用盐酸多西环素说明书. 2013年版. 海口奇力制药股份有限公司.
[2]
注射用盐酸多西环素说明书. 2010年版. 江苏天士力帝益药业有限公司.
[3]
陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012,92(2):76-85.
[4]
周华,李光辉,卓超,等. 中国嗜麦芽窄食单胞菌感染诊治与防控专家共识[J]. 中华医学杂志, 2013,93(16):1203-1213.
[1]
盐酸米诺环素胶囊说明书. 2010年版. 惠氏制药有限公司.
[2]
MINOCIN (Minocycline for injection), 2014,Rempex Pharmaceuticals, U S A.
[3]
MINOCIN (Minocycline capsule), 2013,Almirall Limited,Europe.
[4]
周华,李光辉,卓超,等. 中国嗜麦芽窄食单胞菌感染诊治与防控专家共识[J]. 中华医学杂志, 2013,93(16):1203-1213.
[1]
替加环素说明书. 2013年版,辉瑞投资有限公司.
[2]
Bassetti M , Nicoini L , Repetio E ,et al. Tigecycline used in serious nosocomial infections: a drug use evaluation[J]. BMC Infec Dis, 2010,10:287.
[3]
Ramirez J , Dartois N , Gandjini H ,et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J]. Antimicrob Agents Chemother, 2013,57(4):1756-1762
[4]
Freire AT , Melnyk V , Kim MJ ,et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia[J]. Diagn Microbiol Infect Dis, 2010,68(2):140-151.
[5]
Song JH ,Asian HAP Working Group. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian working group[J]. Am J Infect Control, 2008,36(4Suppl):S83-S92.
[6]
Gardiner D , Dukart G , Cooper A ,et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase Ⅲ clinical trials[J]. Clin Infect Dis, 2010,50(2):229-238.
[7]
Lauf L , Ozsvár Z , Mitha I ,et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis[J]. Diagn Microbiol Infect Dis, 2014,78(4):469-480.
[1]
甲硝唑片剂说明书. 2011年版. 上海信谊药厂有限公司.
[2]
甲硝唑注射液说明书. 2007年版. 河南华利药业有限责任公司.
[3]
Fock KM , Katelaris P , Sugano K ,et al. Second Asia-Pacific Consensus for Helicobacter pylori infection[J]. J Gastroenterol Hepatol, 2009,24(10):1587-1600.
[4]
World Gastroenterology Organization. World gastroenterology organization global guideline: helicobacter pylori in developing countries[J]. J Dig Dis, 2011,12(5):319-326.
[5]
Koletzko S , Jones NL , Goodman KJ ,et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children[J]. J Pediatr Gastroenterol Nutr, 2011,53(2):230-243.
[6]
Chey WD , Wong BC ,Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guidline on the management of helicobacter pylori infection[J]. Am J Gastorenterol, 2007,102(8):1808-1825.
[7]
Malfertheiner P , Megraud F , O'Morain CA ,et al. Management of Helicobacter pylori infection——the Maastricht Ⅳ/Florence Consensus Report[J]. Gut, 2012,61(5):646-666.
[8]
中华医学会消化病学分会. 中国慢性胃炎共识意见[J]. 中华消化杂志, 2013,33(1):5-15.
[9]
Alahdab YO , Kalayci C . Helicobacter pylori: management in 2013[J]. World J Gastroenterol, 2014,20(18):5302-5307.
[10]
FLAGYL
?(metronidazole) tablets
,Pfizer Inc,NY. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/012623s065lbl. pdf.
[11]
FLAGYL
?(metronidazole hydrochloride) 500 mg FOR INJECTION, STERILE
., Pfizer Inc,NY. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/018353s026lbl. pdf.
[12]
Caprilli R , Gassull MA , Escher JC ,et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations[J]. Gut, 2006,55(Suppl 1):i36-58.
[13]
Van Assche G , Dignass A , Reinisch W ,et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations[J]. J Crohns Colitis, 2010,4(1):63-101.
[14]
Rutgeerts P , Hiele M , Geboes K ,et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection[J]. Gastroenterology, 1995,108(6):1617-1621.
[1]
奥硝唑注射液说明书. 2011年版. 山西普德药业股份有限公司.
[2]
Tzivras M , Archimandritis A , Balatsos V ,et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer[J]. Eur J Gastroenterol Hepatol, 1997,9(12):1185-1189.
[3]
Lehmann FS , Drewe J , Terracciano L ,et al. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease[J]. Aliment Pharmacol Ther, 2000,14(3):305-309.
[4]
Caprilli R , Gassull MA , Escher JC ,et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations[J]. Gut, 2006,55(Suppl 1):i36-58.
[5]
Van Assche G , Dignass A , Reinisch W ,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations[J]. J Crohns Colitis, 2010,4(1):63-101.
[6]
Rutgeerts P , Assche GV , Vermeire S ,et al. Ornidazole for prophylaxis of post-operative Crohn's disease: a randomized, double blind, placebo controlled trial[J]. Gastroenterology, 2005,128(4):856-861.
[7]
Malfertheiner P , Megraud F , O'Morain CA ,et al. Management of helicobacter pylori infection——the maastricht Ⅳ/florence consensus report[J]. Gut, 2012,61(5):646-666.
[8]
Fock KM , Katelaris P , Sugano K ,et al. Second Asia-Pacific Consensus for Helicobacter pylori infection[J]. J Gastroenterol Hepatol, 2009,24(10):1587-1600.
[9]
World Gastroenterology Organization. World gastroenterology organization global guideline: helicobacter pylori in developing countries[J]. J Dig Dis, 2011,12(5):319-326.
[1]
利奈唑胺说明书. 2012年版. 辉瑞投资有限公司.
[2]
Liu C , Bayer A , Cosgrove SE ,et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-55.
[3]
Zhang L , Pang Y , Yu X ,et al. Linezolid in the treatment of extensively drug-resistant tuberculosis[J]. Infection, 2014,42(4):705-711.
[4]
Garcia-Prats AJ , Rose PC , Hesseling AC ,et al. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations[J]. Tuberculosis (Edinb), 2014,94(2):93-104.
[5]
Chang KC , Yew WW , Cheung SW ,et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother, 2013,57(7):3445-3449.
[6]
Bolhuis MS , van Altena R , van Hateren K ,et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother, 2013,57(8):3676-3680.
[7]
Lee M , Lee J , Carroll MW ,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis[J]. N Engl J Med, 2012,367(16):1508-1518.
[1]
磷霉素说明书. 2003年版. 东北制药总厂.
[2]
MacLeod DL , Barker LM , Sutherland JL ,et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis[J]. J Antimicrob Chemother, 2009,64(4):829-836.
[3]
Trapnell BC , McColley SA , Kissner DG ,et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection[J]. Am J Respir Crit Care Med, 2012,185(2):171-178.
[1]
盐酸克林霉素胶囊说明书. 2010年版,上海信谊万象药业股份有限公司.
[2]
克林霉素磷酸酯注射液说明书. 2007年版. 河南天方药业股份有限公司.
[3]
Setiawan B ,Ministry of Health Republic of Indonesia. Current malaria management: guideline 2009[J]. Acta Med Indones, 2010,42(4):258-261.
[4]
Lell B , Kremsner PG . Clindamycin as an antimalarial drug: review of clinical trials[J]. Antimicrob Agents Chemother, 2002,46(8):2315-2320.
[5]
Obony CO , Juma EA . Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis[J]. Malar J, 2012,11:2. doi:
10.1186/1475-2875-11-2
.
[6]
中华医学会呼吸病学分会感染学组,中华结核和呼吸杂志编辑委员会. 肺真菌病诊断和治疗专家共识[J]. 中华结核和呼吸杂志, 2007,30(11):821-834.
[7]
Toma E , Thorne A , Singer J ,et al. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group[J]. Clin Infect Dis, 1998,27(3):524-530.
[1]
利福平说明书. 2010年版. 国家药典委员会.中华人民共和国药典.
[2]
陈佰义,何礼贤,胡必杰,等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012,92(2):76-85.
[3]
Tunkel AR , Hartman BJ , Kaplan SL ,et al. Practice guidelines for the management of bacterial meningitis[J]. Clin Infect Dis, 2004,39(1):1267-1284.
[1]
磺胺甲噁唑说明书. 2013年版. 华中药业股份有限公司.
[2]
Tsuji BT , Rybak MJ , Cheung CM ,et al. Communityand health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents[J]. Diagn Microbiol Infect Dis, 2007,58(1):41-47.
[3]
Gould FK , Brindle R , Chadwick PR ,et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK[J]. J Antimicrob Chemother, 2009,63(5):849-861.
[4]
Schmitz GR , Bruner D , Pitotti R ,et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection[J]. Ann Emerg Med, 2010,56(3):283-287.
[5]
Duong M , Markwell S , Peter J ,et al. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient[J]. Ann Emerg Med, 2009,55(5):401-407.
[6]
Tong SY , Andrews RM , Kearns T ,et al. Trimethopim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial[J]. J Paediatr Child Health, 2010,46(3):131-133.
[7]
Markowitz N , Quinn EL , Saravolatz LD . Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection[J]. Ann Intern Med, 1992,117(5):390-398.
[8]
Altunaiji S , Kukuruzovic R , Curtis N ,et al. Antibiotics for whooping cough (pertussis)[J]. Cochrane Database Syst Rev, 2007,18(3):CD004404.
[9]
周华,李光辉,卓超,等. 中国嗜麦芽窄食单胞菌感染诊治和防控专家共识[J]. 中华医学杂志, 2013,93(16):1203-1213.
[10]
中华人民共和国卫生部医政司,卫生部合理用药专家委员会. 国家抗微生物治疗指南[J]. 北京:人民卫生出版社, 2013:98.
[1]
注射用两性霉素B说明书. 2012年版. 华北制药集团新药研究开发有限责任公司.
[2]
Pappas PG , Kauffman CA , Andes D ,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[3]
Bow EJ , Evans G , Fuller J ,et al. Canadian clinical practice guidelines for invasive candidiasis in adults[J]. Can J Infect Dis Med Microbiol, 2010,21(4):e122-150.
[4]
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.http://aidsinfo.nih.gov/guidelines.
[5]
Yu chong C , Fubin C , Jianghan C ,et al. Cryptococcosis in China (1985-2010): review of cases from Chinese database[J]. Mycopathologia, 2012,173(5-6):329-335.
[6]
桑福德. 抗微生物治疗指南[M]. 新译第43版. 北京:中国协和医科大学出版社, 2014:115,117,121.
[7]
注射用两性霉素B脂质体说明书(安浮特克). 2007年版. 上海新先锋药业有限公司.
[8]
AmBisome
®(amphtericin B) liposome for injection[package insert]
. Deerfield, IL:Astellas Pharma US, Inc.
[9]
Ullmann AJ , Akova M , Herbrecht R ,et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)[J]. Clin Microbiol Infect, 2012,18(Suppl 7):53-67.
[10]
Hope WW , Castagnola E , Groll AH ,et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp[J]. Clin Microbiol Infect, 2012,18(Suppl 7):38-52.
[11]
Cornely OA , Bassetti M , Calandra T ,et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients[J]. Clin Microbiol Infect, 2012,18(Suppl 7):19-37.
[12]
Skiada A , Lanternier F , Groll AH ,et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)[J]. Haematologica, 2013,98(4):492-504.
[13]
Cornely OA , Arikan-Akdagli S , Dannaoui E ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014,20(Suppl 3):5-26.
[1]
氟胞嘧啶说明书. 2007年版. 中国药科大学制药有限公司.
[2]
[3]
Pappas PG , Kauffman CA , Andes D ,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[1]
氟康唑氯化钠注射液说明书. 2014年版. 氟康唑胶囊说明书.2013年版.辉瑞投资有限公司.
[2]
[3]
Perfect JR , Dismukes WE , Dromer F ,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010,50(3):291-322.
[4]
Jackson AT , Nussbaum JC , Phulusa J ,et al. A phase Ⅱ randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis[J]. AIDS (London, England), 2012,26(11):1363-1370.
[5]
Loyse A , Wilson D , Meintjes G ,et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis[J]. Clin Infect Dis, 2012,54(1):121-128.
[6]
Nussbaum JC , Jackson A , Namarika D ,et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi[J]. Clin Infect Dis, 2010,50(1):338-344.
[7]
Ministry of Health Malawi. Malawi Guideline for Clinical Management of HIV in Children and Adults (1
st edition)
. 2011http://apps.who.int/medicinedocs/documents/s18802en/s18802en.pdf.
[8]
Pappas PG , Kauffman CA , Andes D ,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[9]
Limper AH , Knox KS , Sarosi GA ,et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients[J]. Am J Respir Crit Care Med, 2011,183(1):96-128.
[1]
伊曲康唑胶囊说明书. 伊曲康唑注射液说明书. 2013年版. 西安杨森制药有限公司.
[2]
Walsh TJ , Anaissie EJ , Denning DW ,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(3):327-360.
[3]
Limper AH , Knox KS , Sarosi GA ,et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients[J]. Am J Respir Crit Care Med, 2011,183(1),96-128.
[4]
Chowdhary A , Meis JF , Guarro J ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi[J]. Clin Microbiol Infect, 2014,20(Suppl 3):47-75.
[5]
Wheat LJ , Freifeld AG , Kleiman MB ,et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2007,45(7):807-825.
[6]
Perfect JR , Dismukes WE , Dromer F ,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
[1]
伏立康唑片剂说明书. 2013年版. 辉瑞投资有限公司.
[2]
Wheat LJ , Freifeld AG , Kleiman MB ,et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2007,45(7):807-825.
[3]
Chapman SW , Dismukes WE , Proia LA ,et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(12):1801-1812.
[4]
Tunkel AR , Glaser CA , Bloch KC ,et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,47(3):303-327.
[5]
Levy ER , McCarty JM , Shane AL ,et al. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series[J]. Clin Infect Dis, 2013,56(11):1573-1578.
[6]
Kim MM , Vikram HR , Kusne S ,et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole[J]. Clin Infect Dis, 2011,53(11):1060-1066.
[7]
Perfect JR , Dismukes WE , Dromer F ,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
[8]
Pappas PG , Kauffman CA , Andes D ,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[9]
Walsh TJ , Pappas P , Winston DJ ,et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J]. N Engl J Med, 2002,346(4):225-234.
[10]
Walsh TJ , Anaissie EJ , Denning DW ,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(3):327-360.
[11]
Chishimba L , Niven RM , Cooley J ,et al. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization[J]. J Asthma, 2012,49(4):423-433
[12]
Chowdhary A , Meis JF , Guarro J ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi[J]. Clin Microbiol Infect, 2014,20(Suppl 3):47-75.
[13]
Tomblyn M , Chiller T , Einsele H ,et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective[J]. Biol Blood Marrow Transplant, 2009,15(10):1143-1238.
[14]
Sharma N , Chacko J , Velpandian T ,et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis[J]. Ophthalmology, 2013,120(4):677-681.
[1]
泊沙康唑口服混悬液说明书. 2013年版. 默沙东制药有限公司.
[2]
Noxafil (posaconazole oral suspension). 2014. Schering-Plough S.A.,France.
[3]
Walsh TJ , Anaissie EJ , Denning DW ,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(3):327-360.
[4]
Chishimba L , Niven RM , Cooley J ,et al. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization[J]. J Asthma, 2012,49(4):423-433
[5]
Gould FK , Denning DW , Elliott TS ,et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy[J]. J Antimicrob Chemother, 2012,67(5):269-289.
[6]
Perfect JR , Dismukes WE , Dromer F ,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
[7]
Cornely OA , Arikan-Akdagli S , Dannaoui E ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014,20(Suppl 3):5-26.
[8]
Elewski B , Pollak R , Ashton S ,et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis[J]. Br J Dermatol, 2012,166(2):389-398.
[9]
Stevens DA , Rendon A , Gaona-Flores V ,et al. Posaconazole therapy for chronic refractory coccidioidomycosis[J]. Chest, 2007,132(3):952-958.
[10]
Pitisuttithum P1 , Negroni R , Graybill JR ,et al. Activity of posaconazole in the treatment of central nervous system fungal infections[J]. J Antimicrob Chemother, 2005,56(4):745-755.
[11]
Chowdhary A , Meis JF , Guarro J ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi[J]. Clin Microbiol Infect, 2014,20(Suppl 3):47-75.
[1]
注射用醋酸卡泊芬净说明书. 2014年版. 默沙东制药有限公司.
[2]
Girmenia C , Barosi G , Piciocchi A ,et al. Primary Prophylaxis of Invasive Fungal Diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by gruppo italiano trapianto midollo osseo (gitmo)[J]. Biol Blood Marrow Transplant, 2014. pii:S1083-8791(14)00133-5.
[3]
Ullmann AJ , Akova M , Herbrecht R ,et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)[J]. Clin Microbiol Infect, 2012,18(Suppl 7):53-67.
[4]
中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)[J]. 中华内科杂志, 2013,52(8):704-709.
[5]
Pappas PG , Kauffman CA , Andes D ,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[6]
Bow EJ , Evans G , Fuller J ,et al. Canadian clinical practice guidelines for invasive candidiasis in adults[J]. Can J Infect Dis Med Microbiol, 2010,21(4):e122-150.
[7]
Tacke D , Buchheidt D , Karthaus M ,et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology[J]. Ann Hematol, 2014,93(9):1449-1456.
[8]
Maertens J , Marchetti O , Herbrecht R ,et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update[J]. Bone Marrow Transplant, 2011,46(5):709-718.
[9]
Mattiuzzi GN , Alvarado G , Giles FJ ,et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies[J]. Antimicrob Agents Chemother, 2006,50(1):143-147.
[10]
Cornely OA , Bassetti M , Calandra T ,et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients[J]. Clin Microbiol Infect, 2012,18(Suppl 7):19-37.
[11]
Walsh TJ , Anaissie EJ , Denning DW ,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(3):327-360.
[12]
Gould FK , Denning DW , Elliott TS ,et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy[J]. J Antimicrob Chemother, 2012,67(2):269-689.
[13]
Esteves F , Medrano FJ , de Armas Y ,et al. Pneumocystis and Pneumocystosis: first meeting of experts from Latin-American and Portuguese-speaking countries- a mini-review[J]. Expert Rev Anti Infect Ther, 2014,12(5):545-548.
[14]
Cornely OA , Arikan-Akdagli S , Dannaoui E ,et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014,20(Suppl 3):5-26.
[15]
桑福德. 抗微生物治疗指南[M]. 新译第43版. 北京:中国协和医科大学出版社, 2014:115-116.
[16]
Betts RF , Nucci M , Talwar D ,et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis[J]. Clin Infect Dis, 2009,48(12):1676-1684.
[17]
Cornely OA , Vehreschild JJ , Vehreschild MJ ,et al. Phase Ⅱ dose escalation study of caspofungin for invasive Aspergillosis[J]. Antimicrob Agents Chemother, 2011,55(12):5798-5803.
[18]
Wurthwein G , Cornely OA , Trame MN ,et al. Population pharmacokinetics of escalating doses of caspofungin in a phase Ⅱ study of patients with invasive aspergillosis[J]. Antimicrob Agents Chemother, 2013,57(4):1664-1671.
[1]
注射用米卡芬净说明书. 2014年版. 安斯泰来制药(中国)有限公司.
[2]
MYCAMINE
®(micafungin sodium) for injection [package insert]
. Northbrook.IL:Astellas Pharma US, Inc.
[3]
MYCAMINE
®(micafungin sodium) for injection [package insert]
. Northbrook.IL:Astellas Ireland Co. Ltd.
[4]
Tomblyn M , Chiller T , Einsele H ,et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective[J]. Biol Blood Marrow Transplant, 2009,15(10):1143-1238.
[5]
Tacke D , Buchheidt D , Karthaus M ,et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology[J]. Ann Hematol, 2014. [Epub ahead of print].
[6]
Maertens J , Marchetti O , Herbrecht R ,et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL-2009 update[J]. Bone Marrow Transplant, 2011,46(5):709-718.
[7]
Pappas PG , Kauffman CA , Andes D ,et al. Infectious Diseases Society of A. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009,48(5):503-535.
[8]
Girmenia C , Barosi G , Piciocchi A ,et al. Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)[J]. Biol Blood Marrow Transplant, 2014,20(8):1080-1088.
[9]
Baden LR , Bensinger W , Angarone M ,et al. Prevention and treatment of cancer-related infections[J]. J Natl Compr Canc Netw, 2012,10(11):1412-1445.
[10]
桑福德. 抗微生物治疗指南[M]. 新译第43版. 北京:中国协和医科大学出版社, 2014:115-116.
备注信息
A
刘又宁,100853北京,解放军总医院呼吸科
B
(排名不分先后):邸秀珍,顾恒琼,姜悦,李培,李颖,林东昉,刘斌,马莹,倪文涛,秦晓华,苏鑫,孙文逵,王明华,谢社玲,徐小勇,张萍,赵旭为本共识收集资料
评论 (0条)
注册 登录
时间排序
- 时间排序
暂无评论,发表第一条评论抢沙发
最新推荐
更多
本期导读
中华危重病急救医学 2022,34(04)
本期导读
中华烧伤杂志 2021,37(06)
本期导读
中华眼科杂志 2021,57(05)
本期导读
中华眼科杂志 2021,57(06)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手(体验版)
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中

N/A
N/A
快照内容由人工智能生成,供您参考。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。
0/50
很抱歉,当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。

你好! 今天我能为您提供什么帮助?
0/30
of
很抱歉,当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用